These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 22490713)

  • 1. [Effect of early high-loading-dose tirofiban on platelet activity in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention].
    Ren XN; Wang LF; Wang MS; Xu L
    Zhonghua Xin Xue Guan Bing Za Zhi; 2012 Feb; 40(2):131-5. PubMed ID: 22490713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial.
    Valgimigli M; Tebaldi M; Campo G; Gambetti S; Bristot L; Monti M; Parrinello G; Ferrari R;
    JACC Cardiovasc Interv; 2012 Mar; 5(3):268-77. PubMed ID: 22440491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single high-dose bolus tirofiban with high-loading-dose clopidogrel in primary coronary angioplasty.
    Bilsel T; Akbulut T; Yesilcimen K; Terzi S; Sayar N; Dayi SU; Akgoz H; Ergelen M; Ciloglu F
    Heart Vessels; 2006 Mar; 21(2):102-7. PubMed ID: 16550311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Short- or long-outcome of early tirofiban in ST-segment elevated acute myocardial infarction undergoing elective percutaneous coronary intervention].
    Zhang Y; Gao C; Li M; Liu H; Wang X; Yang H; Wang X; Zhu Z; Hu D
    Zhonghua Nei Ke Za Zhi; 2014 Apr; 53(4):273-7. PubMed ID: 24857299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet inhibition by increased tirofiban dosing during primary coronary angioplasty for ST elevation myocardial infarction.
    Kralisz P; Dobrzycki S; Nowak K; Kochman W; Gajewska-Bachórzewska H; Gugała K; Mezyński G; Prokopczuk P; Zuk J; Korecki J; Poniatowski B; Musiał W
    Kardiol Pol; 2004 May; 60(5):459-67. PubMed ID: 15247961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effects of intracoronary tirofiban bolus administration following upstream intravenous treatment in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the ICT-AMI study.
    Zhu TQ; Zhang Q; Qiu JP; Jin HG; Lu L; Shen J; Zhao LP; Zhang RY; Hu J; Yang ZK; Shen WF
    Int J Cardiol; 2013 May; 165(3):437-43. PubMed ID: 21940058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome.
    ten Berg JM; van 't Hof AW; Dill T; Heestermans T; van Werkum JW; Mosterd A; van Houwelingen G; Koopmans PC; Stella PR; Boersma E; Hamm C;
    J Am Coll Cardiol; 2010 Jun; 55(22):2446-55. PubMed ID: 20510211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy and safety of tirofiban use after successful percutaneous coronary intervention for patients with moderate to high risk non-ST segment elevation acute coronary syndromes].
    Zhang Y; Gao CY; Zhu ZY; Liu HZ; Wang XP; Yang HH; Li MW; Wang XQ; Qi DT; Hu DY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2013 Sep; 41(9):731-5. PubMed ID: 24331798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.
    Valgimigli M; Campo G; Percoco G; Bolognese L; Vassanelli C; Colangelo S; de Cesare N; Rodriguez AE; Ferrario M; Moreno R; Piva T; Sheiban I; Pasquetto G; Prati F; Nazzaro MS; Parrinello G; Ferrari R;
    JAMA; 2008 Apr; 299(15):1788-99. PubMed ID: 18375998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiplatelet effect of ticagrelor compared to tirofiban in non-ST-segment elevation ACS patients undergoing PCI. The result of the TE-CLOT trial.
    Kim JS; Han DC; Jeong YH; Park DW; Sohn CB; Hwang KW; Lee SH; Choi JH; Chon MK; Lee SY; Hwang J; Kim IS; Lee SM; Han J; Noh M; Kim CH; Chun KJ; Park YH; Kim JH
    Thromb Haemost; 2016 Jan; 115(1):213-21. PubMed ID: 26581884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of standard-dose versus half-dose tirofiban in patients with non-ST elevation acute coronary syndromes undergoing early percutaneous coronary intervention.
    Li W; Fu X; Xue H; Wang Y; Wang X; Zhao Y; Geng W; Yang Z; Gu X; Hao G; Jiang Y; Fan W; Wu W; Li S
    Cardiovasc Ther; 2013 Aug; 31(4):210-4. PubMed ID: 22954393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Ernst NM; Suryapranata H; Miedema K; Slingerland RJ; Ottervanger JP; Hoorntje JC; Gosselink AT; Dambrink JH; de Boer MJ; Zijlstra F; van 't Hof AW
    J Am Coll Cardiol; 2004 Sep; 44(6):1187-93. PubMed ID: 15364318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term effect of upstream administration in comparison to deferred injection of tirofiban on patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Jia Z; Guo M; Zhang YQ; Liang HQ; Song Y
    J Interv Cardiol; 2013 Aug; 26(4):332-9. PubMed ID: 23844823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of tirofiban infusion on clinical and angiographic outcomes of patients with STEMI undergoing primary PCI.
    Kaymaz C; Keleş N; Özdemir N; Tanboğa İH; Demircan HC; Can MM; Koca F; İzgi İA; Özkan A; Türkmen M; Kırma C; Esen AM
    Anatol J Cardiol; 2015 Nov; 15(11):899-906. PubMed ID: 25868037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial.
    Gargiulo G; Esposito G; Avvedimento M; Nagler M; Minuz P; Campo G; Gragnano F; Manavifar N; Piccolo R; Tebaldi M; Cirillo P; Hunziker L; Vranckx P; Leonardi S; Heg D; Windecker S; Valgimigli M
    Circulation; 2020 Aug; 142(5):441-454. PubMed ID: 32795098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical outcomes and safety of primary percutaneous coronary intervention combined with tirofiban therapy in patients with acute ST-segment elevation myocardial infarction].
    Shen J; Zhang Q; Zhang RY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2007 Nov; 35(11):1005-9. PubMed ID: 18269820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent coronary no flow after wire insertion is an early and readily available mortality risk factor despite successful mechanical intervention in acute myocardial infarction: a pooled analysis from the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.
    Valgimigli M; Campo G; Malagutti P; Anselmi M; Bolognese L; Ribichini F; Boccuzzi G; de Cesare N; Rodriguez AE; Russo F; Moreno R; Biondi-Zoccai G; Penzo C; Díaz Fernández JF; Parrinello G; Ferrari R
    JACC Cardiovasc Interv; 2011 Jan; 4(1):51-62. PubMed ID: 21251629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.
    Garg S; Sarno G; Serruys PW; Rodriguez AE; Bolognese L; Anselmi M; De Cesare N; Colangelo S; Moreno R; Gambetti S; Monti M; Bristot L; Bressers M; Garcia-Garcia HM; Parrinello G; Campo G; Valgimigli M;
    JACC Cardiovasc Interv; 2011 Jan; 4(1):66-75. PubMed ID: 21251631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tirofiban for myocardial infarction.
    Juwana YB; Suryapranata H; Ottervanger JP; van 't Hof AW
    Expert Opin Pharmacother; 2010 Apr; 11(5):861-6. PubMed ID: 20210689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal platelet inhibition in patients undergoing PCI: data from the Multicenter Registry of High-Risk Percutaneous Coronary Intervention and Adequate Platelet Inhibition (MR PCI) study.
    Mardikar HM; Hiremath MS; Moliterno DJ; Mathew R; Arora R; Deo D; Hiremath JS; Deshpande NV; Khan A; Joseph J; Mukherjee D
    Am Heart J; 2007 Aug; 154(2):344.e1-5. PubMed ID: 17643586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.